Interleukin-2 and type 1 diabetes: New therapeutic perspectives

Diabetes and Metabolism

Volumn 38, Issue 5, 2012, Pages 387-391

  Hartemann, A ^a,b   Bourron, O ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

IL 2; Regulatory cells; Review; Type 1 diabetes

Indexed keywords

INSULIN; INTERLEUKIN 2;

CD4+ T LYMPHOCYTE; CELL DESTRUCTION; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LOW DRUG DOSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS FUNCTION; PATHOGENESIS; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INSULIN; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MICE; PANCREAS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84869117505     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.05.006     Document Type: Review

References (40)

1. Asano M., Toda M., Sakaguchi N., Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996, 184:387-396.
2. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
3. Malek T.R., Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010, 33:153-165.
4. Ziegler S.F. FOXP3: of mice and men. Annu Rev Immunol 2006, 24:209-226.
5. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203:1701-1711.
6. Curotto de Lafaille M.A., Lafaille J.J. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?. Immunity 2009, 30:626-635.
7. Chatenoud L. Natural and induced T CD4+CD25+FOXP3+ regulatory T cells. Methods Mol Biol 2011, 677:3-13.
8. Belkaid Y., Chen W. Regulatory ripples. Nat Immunol 2010, 11:1077-1078.
9. Papiernik M., de Moraes M.L., Pontoux C., Vasseur F., Penit C. Regulatory CD4T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 1998, 10:371-378.
10. O'Gorman W.E., Dooms H., Thorne S.H., Kuswanto W.F., Simonds E.F., Krutzik P.O., et al. The initial phase of an immune response functions to activate regulatory T cells. J Immunol 2009, 183:332-339.
11. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., Sharpe A., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440.
12. Grinberg-Bleyer Y., Baeyens A., You S., Elhage R., Fourcade G., Gregoire S., et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010, 207:1871-1878.
13. Szanya V., Ermann J., Taylor C., Holness C., Fathman C.G. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 2002, 169:2461-2465.
14. Tarbell K.V., Petit L., Zuo X., Toy P., Luo X., Mqadmi A., et al. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 2007, 204:191-201.
15. Chen Z., Herman A.E., Matos M., Mathis D., Benoist C. Where CD4+CD25+T reg cells impinge on autoimmune diabetes. J Exp Med 2005, 202:1387-1397.
16. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
17. Brusko T.M., Wasserfall C.H., Clare-Salzler M.J., Schatz D.A., Atkinson M.A. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005, 54:1407-1414.
18. Putnam A.L., Vendrame F., Dotta F., Gottlieb P.A. CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun 2005, 24:55-62.
19. Battaglia M., Stabilini A., Migliavacca B., Horejs-Hoeck J., Kaupper T., Roncarolo M.G. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006, 177:8338-8347.
20. Brusko T., Wasserfall C., McGrail K., Schatz R., Viener H.L., Schatz D., et al. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 2007, 56:604-612.
21. Schneider A., Rieck M., Sanda S., Pihoker C., Greenbaum C., Buckner J.H. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 2008, 181:7350-7355.
22. Long S.A., Walker M.R., Rieck M., James E., Kwok W.W., Sanda S., et al. Functional islet-specific Treg can be generated from CD4+CD25-T cells of healthy and type 1 diabetic subjects. Eur J Immunol 2009, 39:612-620.
23. Ferraro A., Socci C., Stabilini A., Valle A., Monti P., Piemonti L., et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011, 60:2903-2913.
24. Marwaha A.K., Crome S.Q., Panagiotopoulos C., Berg K.B., Qin H., Ouyang Q., et al. Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol 2010, 185:3814-3818.
25. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martinez-Llordella M., Ashby M., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009, 10:1000-1007.
26. Yamanouchi J., Rainbow D., Serra P., Howlett S., Hunter K., Garner V.E., et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 2007, 39:329-337.
27. Vella A., Cooper J.D., Lowe C.E., Walker N., Nutland S., Widmer B., et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet 2005, 76:773-779.
28. Concannon P., Rich S.S., Nepom G.T. Genetics of type 1A diabetes. N Engl J Med 2009, 360:1646-1654.
29. Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28:687-697.
30. Glisic-Milosavljevic S., Waukau J., Jailwala P., Jana S., Khoo H.J., Albertz H., et al. At-risk and recent-onset type 1 diabetic subjects have increased apoptosis in the CD4+CD25+ T-cell fraction. PLoS One 2007, 2:e146.
31. Jailwala P., Waukau J., Glisic S., Jana S., Ehlenbach S., Hessner M., et al. Apoptosis of CD4+ CD25(high) T cells in type 1 diabetes may be partially mediated by IL-2 deprivation. PLoS One 2009, 4(8):e6527.
32. Long S.A., Cerosaletti K., Bollyky P.L., Tatum M., Shilling H., Zhang S., et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010, 59:407-415.
33. Monti P., Scirpoli M., Maffi P., Piemonti L., Secchi A., Bonifacio E., et al. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes 2008, 57:2341-2347.
34. Ahmadzadeh M., Rosenberg S.A. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006, 107:2409-2414.
35. Saadoun D., Rosenzwajg M., Joly F., Six A., Carrat F., Thibault V., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011, 365:2067-2077.
36. Wilke C.M., Wu K., Zhao E., Wang G., Zou W. Prognostic significance of regulatory T cells in tumor. Int J Cancer 2010, 127:748-758.
37. Colombo M.P., Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007, 7:880-887.
38. Nishikawa H., Sakaguchi S., Regulatory T cells in tumor immunity. Int J Cancer 2010, 127:759-767.
39. Krieg C., Letourneau S., Pantaleo G., Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 2010, 107:11906-11911.
40. Levin A.M., Bates D.L., Ring A.M., Krieg K., Lin J.T., Su L., et al. Exploiting a natural conformational switch to engineer an interleukin-2 "superkine". Nature 2012, 10.1038/nature10975.